Related Experiment Videos

Theophylline pharmacokinetics in premature infants with apnea

The Journal of Pediatrics
|November 1, 1976
PubMed

Insights

Theophylline elimination is slow and variable in low-birth-weight infants treated for apnea. Careful monitoring and adjusted dosing are crucial for safe and effective theophylline therapy in neonates.

Area of Science:

  • Neonatal Pharmacology
  • Pediatric Clinical Pharmacy

Background:

  • Apnea is common in low-birth-weight infants.
  • Theophylline is used to treat primary apnea in neonates.

Purpose of the Study:

  • To characterize the pharmacokinetics of theophylline in low-birth-weight infants.
  • To provide dosing recommendations for theophylline in this population.

Main Methods:

  • Eight low-birth-weight infants received theophylline for apnea.
  • Theophylline levels were measured using high-pressure liquid chromatography.
  • Pharmacokinetic parameters including half-life, volume of distribution, and clearance were calculated.

Main Results:

  • Theophylline exhibited a prolonged half-life (13-29 hours) and a large volume of distribution (0.65-2.86 L/kg).
  • Body clearance of theophylline was low (23-68 mL/hr/kg).
  • Significant variability in theophylline elimination was observed.

Conclusions:

  • Theophylline elimination is extremely slow and variable in low-birth-weight infants.
  • Therapeutic drug monitoring and individualized dosing are essential.
  • A suggested initial regimen includes a loading dose of 6 mg/kg and a maintenance dose of 2 mg/kg every 12 hours, adjusted for maturation.

Related Concept Videos